drugsTreatmentPhase 2

ENV-501

ENV-501 is an experimental antibody-drug conjugate from Hummingbird Bioscience in phase 2 trials for melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, aimed at HER3.

ENV-501 is an antibody-drug conjugate developed by Hummingbird Bioscience. Its target is HER3. ClinicalTrials.gov describes the intervention as: ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06956690, plans to enrol 180 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How it works, step by step · animated schematic, not to scale; chosen from the modality "ADC"

Antibody-drug conjugate (ADC) →

Modality

ADC

Mechanism

Antibody-drug conjugate directed at HER3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

ENV-501

intervention: ENV-501

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.